Cabergoline in Metastatic Breast Cancer

Summary

Prolactin is a hormone produced in the pituitary gland. Previous studies have revealed that elevated levels of the hormone prolactin might be associated with an increased risk of breast cancer. Cabergoline has been shown to lower prolactin levels in the blood. The purpose of this study is to evaluate the effectiveness of cabergoline in treating metastatic breast cancer disease in those who test positive for the prolactin receptor.

Timeline

Start

2013-02-11

Primary completion

2015-12-15

Completion

2017-10-27

Drugs

Indications